First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

Prior treatment

• Prior liver transplant
• Prior immuno-oncology treatment

Other illness

• Other advanced cancers requiring systemic therapy

Other

• Known fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or mixed cholangiocarcinoma
• ECOG performance status ≥ 3
• Uncontrolled comorbidities despite treatment
• Participation in interventional clinical trials at enrollment
• Deemed unsuitable by investigator

• Participants aged ≥ 18 years at the time of consent
• Participants with unresectable hepatocellular carcinoma (uHCC), defined as disease not eligible for curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies
• Child-Pugh class A (total score 5-6)
• Participants who have not received prior systemic drug therapy for uHCC
  • Participants who relapsed more than 6 months after completion of postoperative adjuvant therapy are eligible
  • Participants who received lenvatinib in combination with transarterial chemoembolization (TACE) are eligible if the treating physician determined they were eligible for TACE; participants are excluded if TACE eligibility at the time of lenvatinib initiation is unclear
• Participants scheduled to initiate nivolumab plus ipilimumab combination therapy between March 1, 2026 and February 28, 2027
  • Nivolumab plus ipilimumab combination therapy is defined as nivolumab 80 mg and ipilimumab 3 mg/kg administered intravenously every 3 weeks for 4 cycles, followed by nivolumab monotherapy at 240 mg every 2 weeks or 480 mg every 4 weeks
• Participants who provide written informed consent prior to initiation of nivolumab plus ipilimumab therapy